comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
Published 4 years ago • 1K plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
58:25
molecular targeted therapies for advanced hcc
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
1:26
evaluating systemic therapies available for frontline treatment of hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
6:08
imbrave150 trial: combination therapy in advanced hcc
-
2:09
comparing afami-cel with existing treatments in synovial sarcoma
-
1:11
regorafenib vs sorafenib in the treatment of liver cancer
-
4:14
imbrave150 trial: frontline treatment of advanced hcc
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
1:17
advice on decision making for frontline treatment of hcc
-
3:45
how goals help to determine frontline treatment in hcc
-
1:07
recent advancements for the treatment of liver cancer
-
1:24
phase iii findings for lenvatinib in hcc
-
1:33
current agents approved for treatment of hcc
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc